12:25 PM EST - Optimi Health : Announced that it has entered into a supply agreement with Filament Health, a clinical-stage natural psychedelic drug development company.
Optimi has been engaged by Filament to supply psilocybin mushrooms cultivated in Optimi’s recently inaugurated 20,000 square foot Princeton, British Columbia facility in the form of whole, dried mushroom fruiting bodies for potential drug development, testing, and analysis by Filament’s research team. Optimi Health
shares C.OPTI are trading up $0.09 at $0.45.
